FDA scientists question Capricor data; Legend CEO steps down

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Capricor Therapeutics

Capricor stock falls 61% as FDA challenges Deramiocel efficacy; Phase 3 DMD trial missed primary endpoint, cardiac data show no benefit. Signal for biotech acquirers: late-stage efficacy gaps elevate regulatory risk, erode valuations, tighten clinical M&A discipline.